. Le-niveau-d, étude était renseigné pour 114 patients (pas d'équivalence de niveau d'études ou ne souhaitant pas répondre pour 30 patients). 8 patients avaient terminé le niveau primaire (5,5% des patients 14 un niveau professionnel : diplôme professionnel type, 17 le niveau collège, pp.42-75

S. Chu, J. Buehler, L. Lieb, G. Beckett, L. Conti et al., Causes of death among persons reported with AIDS., American Journal of Public Health, vol.83, issue.10, pp.1429-1461, 1993.
DOI : 10.2105/AJPH.83.10.1429

?. Khandazhinskaya and E. Shirokova, AZT 5'-Phosphonates: Achievements and Trends in the Treatment and Prevention of HIV Infection, Acta Naturae, vol.5, issue.3, pp.54-61, 2013.

K. Bhaskaran, O. Hamouda, and M. Sannes, Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population, JAMA, vol.300, issue.1, pp.51-60, 2008.
DOI : 10.1001/jama.300.1.51

C. Lewden, G. Chene, P. Morlat, F. Raffi, M. Dupon et al., HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population, J Acquir Immune Defic Syndr, vol.46, issue.1, pp.72-79, 1999.
URL : https://hal.archives-ouvertes.fr/inserm-00170726

A. Therapy, C. Collaboration, M. Zwahlen, R. Harris, M. May et al., Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, Int J Epidemiol. déc, vol.38, issue.6, pp.1624-1657, 2009.

I. and S. France, Decouvertes de séropositivité VIH et SIDA . Point épidémiologique. [Internet]. 2016 [cité 3 sept 2016]. Disponible sur: http://invs.santepubliquefrance.fr/fr, 124392.

L. Vu, S. , L. Strat, Y. Barin, F. Pillonel et al., Population-based HIV-1 incidence in France, 2003?08: a modelling analysis, Lancet Infect Dis. oct, vol.10, issue.10, pp.682-689, 2010.

F. Santé-publique, Bulletin des réseaux de surveillance des infections sexuellement transmissibles Rénago, Renachla et ResIST, Disponible sur, 2017.

P. Morlat, Prise en charge médicale des personnes vivant avec le VIH, recommandations du groupe d'experts: rapport 2013 sous la direction du Pr Philippe Morlat et sous l'égide du CNS et de l'ANRS. La Documentation Française, 2013.

R. Guignard, F. Beck, J. Richard, and A. Lermenier, La consommation de tabac en France en 2014: caractéristiques et évolutions récentes, Evolutions. janv, issue.31, pp.1-6, 2015.

J. Richard, C. Palle, R. Guignard, V. Nguyen-thanh, F. Beck et al., La consommation d'alcool en France en 2014, avrilEvolutions, issue.32, pp.1-6, 2015.

E. Lanoy, J. Spano, F. Bonnet, M. Guiguet, F. Boué et al., The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study, International Journal of Cancer, vol.45, issue.2, pp.467-75, 2011.
DOI : 10.1086/518606

M. Guiguet, F. Boué, J. Cadranel, J. Lang, E. Rosenthal et al., Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study, The Lancet Oncology, vol.10, issue.12, pp.1152-1161, 2009.
DOI : 10.1016/S1470-2045(09)70282-7

S. Lang, M. Mary-krause, L. Cotte, J. Gilquin, M. Partisani et al., Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, vol.24, issue.8, pp.1228-1258, 2010.
DOI : 10.1097/QAD.0b013e328339192f

S. Lang, M. Mary-krause, L. Cotte, J. Gilquin, and M. Partisani, Impact of Individual Antiretroviral Drugs on the Risk of Myocardial Infarction in Human Immunodeficiency Virus???Infected Patients<subtitle>A Case-Control Study Nested Within the French Hospital Database on HIV ANRS Cohort CO4</subtitle><alt-title>Antiretroviral Drugs, Risk of MI, and HIV</alt-title>, Archives of Internal Medicine, vol.170, issue.14, pp.1228-1266, 2010.
DOI : 10.1001/archinternmed.2010.197

F. Dauchy, S. Lawson-ayayi, R. De-la-faille, F. Bonnet, C. Rigothier et al., Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy, Kidney International, vol.80, issue.3, pp.302-311, 2011.
DOI : 10.1038/ki.2011.124

F. Goehringer, F. Bonnet, D. Salmon, P. Cacoub, A. Georget et al., Causes de décès des personnes séropositives pour le VIH en succès immunovirologique en, 2010.

F. Coutlée, A. Pokomandy, . De, and E. Franco, Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sex Health, pp.547-55, 2012.

C. Piketty, H. Selinger-leneman, A. Bouvier, A. Belot, M. Mary-krause et al., Incidence of HIV-Related Anal Cancer Remains Increased Despite Long-Term Combined Antiretroviral Treatment: Results From the French Hospital Database on HIV, Journal of Clinical Oncology, vol.30, issue.35, pp.4360-4366, 2012.
DOI : 10.1200/JCO.2012.44.5486

A. Chaturvedi, M. Madeleine, R. Biggar, and E. Engels, Risk of Human Papillomavirus???Associated Cancers Among Persons With AIDS, JNCI: Journal of the National Cancer Institute, vol.101, issue.16, pp.1120-1150, 2009.
DOI : 10.1093/jnci/djp205

A. Fauci, Multifactorial nature of human immunodeficiency virus disease: implications for therapy, Science, vol.262, issue.5136, pp.1011-1019, 1993.
DOI : 10.1126/science.8235617

A. Fauci, G. Pantaleo, S. Stanley, and D. Weissman, Immunopathogenic Mechanisms of HIV Infection, Annals of Internal Medicine, vol.124, issue.7, pp.654-63, 1996.
DOI : 10.7326/0003-4819-124-7-199604010-00006

Y. Cao, L. Qin, L. Zhang, J. Safrit, and D. Ho, Virologic and Immunologic Characterization of Long-Term Survivors of Human Immunodeficiency Virus Type 1 Infection, New England Journal of Medicine, vol.332, issue.4, pp.201-209, 1995.
DOI : 10.1056/NEJM199501263320401

N. Pakker, D. Notermans, R. De-boer, M. Roos, F. De-wolf et al., Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation, Nature Medicine, vol.41, issue.2, pp.208-222, 1998.
DOI : 10.1016/0022-1759(89)90260-3

J. Gilquin, C. Piketty, V. Thomas, G. Gonzales-canali, L. Belec et al., Acute cytomegalovirus infection in AIDS patients with CD4 counts above 100 x 10(6) cells/l following combination antiretroviral therapy including protease inhibitors, AIDS Lond Engl. nov, vol.11, issue.13, pp.1659-60, 1997.

M. Schneider, J. Borleffs, R. Stolk, C. Jaspers, and A. Hoepelman, Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. The Lancet, janv, vol.353, issue.9148, pp.201-204, 1999.

R. Hirschtick, J. Glassroth, M. Jordan, T. Wilcosky, J. Wallace et al., Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus, New England Journal of Medicine, vol.333, issue.13, pp.845-51, 1995.
DOI : 10.1056/NEJM199509283331305

R. Dray-spira, K. Wilson-d-'almeida, C. Aubrière, F. Marcellin, C. Spire et al., Etat de santé de la population vivant avec le VIH en France en 2011 et caractéristiques des personnes récemment diagnostiquées

K. Hayakawa, I. Itoda, K. Shimuta, H. Takahashi, and M. Ohnishi, Serogroup W in Man Who Has Sex with Men, Japan, Emerging Infectious Diseases, vol.20, issue.9, p.1585, 2014.
DOI : 10.3201/eid2009.140349

F. Lert, M. Annequin, L. Tron, C. Aubrière, C. Hamelin et al., Situation socioéconomique des personnes vivant avec le VIH suivies à l'hôpital en France métropolitaine en 2011. Premiers résultats de l'enquête ANRS-Vespa2, Bull Epidémiol Hebd, issue.26?27, pp.293-302, 2013.

L. Bratcher and V. Sahasrabuddhe, The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research, Infectious Agents and Cancer, vol.5, issue.1, p.8, 2010.
DOI : 10.1186/1750-9378-5-8

T. Dieye, P. Sow, T. Simonart, A. Guèye-ndiaye, S. Popper et al., Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals, Vaccine, vol.20, issue.5-6, pp.905-913, 2001.
DOI : 10.1016/S0264-410X(01)00383-8

S. Madhi, L. Kuwanda, L. Saarinen, C. Cutland, R. Mothupi et al., Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children, Vaccine, vol.23, issue.48-49, pp.5517-5542, 2005.
DOI : 10.1016/j.vaccine.2005.07.038

D. Bertolini, L. Costa, I. Van-der-heijden, H. Sato, H. Marques et al., Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults, Vaccine, vol.30, issue.37, pp.5482-5488, 2012.
DOI : 10.1016/j.vaccine.2012.06.069

L. Aurpibul, T. Puthanakit, T. Sirisanthana, and V. Sirisanthana, Response to Measles, Mumps, and Rubella Revaccination in HIV-Infected Children with Immune Recovery after Highly Active Antiretroviral Therapy, Clinical Infectious Diseases, vol.45, issue.5, pp.637-679, 2007.
DOI : 10.1086/520651

S. Kourkounti, N. Mavrianou, V. Paparizos, K. Kyriakis, M. Hatzivassiliou et al., Immune response to hepatitis a vaccination in HIV-infected men in Greece, International Journal of STD & AIDS, vol.3, issue.1, pp.464-471, 2012.
DOI : 10.2217/hiv.09.39

B. Rosas, L. , M. Aumatell, C. , R. Torrell et al., Efectos de la vacunaci??n antigripal sobre el porcentaje de linfocitos T CD4 positivos en pacientes VIH 1/2 positivos: estudio de una cohorte, Gaceta Sanitaria, vol.23, issue.4, pp.315-336, 2009.
DOI : 10.1016/j.gaceta.2008.10.011

D. Skiest and T. Machala, Comparison of the effects of acute Influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts, Journal of Clinical Virology, vol.26, issue.3, pp.307-322, 2003.
DOI : 10.1016/S1386-6532(02)00047-1

T. Bonetti, R. Succi, L. Weckx, L. Tavares-lopes, and M. De-moraes-pinto, Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women, Vaccine, vol.22, issue.27-28, pp.3707-3719, 2004.
DOI : 10.1016/j.vaccine.2004.03.023

M. Saindou, C. Chidiac, P. Miailhes, N. Voirin, D. Baratin et al., Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods, HIV Medicine, vol.162, issue.4, pp.203-210, 2008.
DOI : 10.1086/314890

URL : https://hal.archives-ouvertes.fr/hal-00428147

M. Dworkin, J. Ward, D. Hanson, J. Jones, and J. Kaplan, Pneumococcal Disease among Human Immunodeficiency Virus-Infected Persons: Incidence, Risk Factors, and Impact of Vaccination, Clinical Infectious Diseases, vol.32, issue.5, pp.794-800, 2001.
DOI : 10.1086/319218

I. Grau, C. Ardanuy, J. Liñares, D. Podzamczer, M. Schulze et al., Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease, HIV Medicine, vol.10, issue.8, pp.488-95, 2009.
DOI : 10.1111/j.1468-1293.2009.00717.x

F. Kroon, J. Van-dissel, E. Ravensbergen, P. Nibbering, and R. Van-furth, Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults, Vaccine, vol.19, issue.7-8, pp.886-894, 2000.
DOI : 10.1016/S0264-410X(00)00232-2

K. Klugman, S. Madhi, R. Huebner, R. Kohberger, N. Mbelle et al., A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection, New England Journal of Medicine, vol.349, issue.14, pp.1341-1349, 2003.
DOI : 10.1056/NEJMoa035060

M. Glesby, W. Watson, C. Brinson, R. Greenberg, J. Lalezari et al., Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine, Journal of Infectious Diseases, vol.212, issue.1, pp.18-27, 2015.
DOI : 10.1093/infdis/jiu631

J. Lujan-zilbermann, M. Warshaw, P. Williams, S. Spector, M. Decker et al., Immunogenicity and Safety of 1 vs 2 Doses of Quadrivalent Meningococcal Conjugate Vaccine in Youth Infected with Human Immunodeficiency Virus, The Journal of Pediatrics, vol.161, issue.4, pp.676-681, 2012.
DOI : 10.1016/j.jpeds.2012.04.005

G. Siberry, M. Warshaw, P. Williams, S. Spector, M. Decker et al., Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children, 47?52. 51. HCSP. Vaccination contre les infections invasives à méningocoque C au-delà de 24 ans, notamment chez les hommes ayant des relations sexuelles avec d'autres hommes (HSH) [Internet]. Paris: Haut Conseil de la Santé Publique; 2014 nov, 2012.
DOI : 10.1097/INF.0b013e318236c67b

P. Belaunzarán-zamudio, M. García-león, R. Wong-chew, A. Villasís-keever, J. Cuellar-rodríguez et al., Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART, Vaccine, vol.27, issue.50, pp.7059-64, 2009.
DOI : 10.1016/j.vaccine.2009.09.063

J. Angel, P. Walpita, R. Lerch, M. Sidhu, M. Masurekar et al., Vaccine-Associated Measles Pneumonitis in an Adult with AIDS, Annals of Internal Medicine, vol.129, issue.2, pp.104-110, 1998.
DOI : 10.7326/0003-4819-129-2-199807150-00007

J. Lin and K. Nichol, Excess Mortality Due to Pneumonia or Influenza During Influenza Seasons Among Persons With Acquired Immunodeficiency Syndrome, Archives of Internal Medicine, vol.161, issue.3, pp.441-447, 2001.
DOI : 10.1001/archinte.161.3.441

K. Neuzil, C. Coffey, E. Mitchel, and M. Griffin, Cardiopulmonary Hospitalizations During Influenza Season in Adults and Adolescents With Advanced HIV Infection, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.34, issue.3, pp.304-311, 1999.
DOI : 10.1097/00126334-200311010-00008

K. Kunisaki and E. Janoff, Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses, The Lancet Infectious Diseases, vol.9, issue.8, pp.493-504, 2009.
DOI : 10.1016/S1473-3099(09)70175-6

A. Anema, E. Mills, J. Montaner, J. Brownstein, and C. Cooper, Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis, HIV Medicine, vol.3, issue.1, pp.57-61, 2008.
DOI : 10.7326/0003-4819-131-6-199909210-00006

S. Tasker, J. Treanor, W. Paxton, and M. Wallace, Efficacy of Influenza Vaccination in HIV-Infected Persons, Annals of Internal Medicine, vol.131, issue.6, pp.430-433, 1999.
DOI : 10.7326/0003-4819-131-6-199909210-00006

D. Skiest and T. Machala, Comparison of the effects of acute Influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts, Journal of Clinical Virology, vol.26, issue.3, pp.307-322, 2003.
DOI : 10.1016/S1386-6532(02)00047-1

C. Larsen, G. Pialoux, D. Salmon, D. Antona, L. Strat et al., Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France ?: Hepatitis B prevalence in the HOPS, the HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, pp.879-86, 1996.

L. Piroth, S. Pol, K. Lacombe, P. Miailhes, A. Rami et al., Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study, Journal of Hepatology, vol.53, issue.6, pp.1006-1018, 2010.
DOI : 10.1016/j.jhep.2010.04.041

K. Lacombe, A. Boyd, F. Lavocat, C. Pichoud, J. Gozlan et al., High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients, Hepatology, vol.18, issue.3, pp.912-934, 2013.
DOI : 10.1111/j.1365-2893.2010.01321.x

K. Lacombe, V. Massari, P. Girard, L. Serfaty, J. Gozlan et al., Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV, AIDS, vol.20, issue.3, pp.419-446, 2006.
DOI : 10.1097/01.aids.0000200537.86984.0e

D. Potsch, L. A. Camacho, S. Tuboi, L. Villar, J. Miguel et al., Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults, Vaccine, vol.30, issue.41, pp.5973-5980, 2012.
DOI : 10.1016/j.vaccine.2012.07.028

J. Ni, Y. Xiong, W. Xiu, and L. , Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard ose vaccination: a metaanalysis, Int J STD AIDS. févr, vol.24, issue.2, pp.177-199, 2013.

M. Mizusawa, D. Perlman, D. Lucido, and N. Salomon, Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons, International Journal of STD & AIDS, vol.31, issue.1, pp.201-207, 2014.
DOI : 10.1016/j.vaccine.2012.12.047

M. Winnock, F. Bani-sadr, E. Pambrun, M. Loko, C. Lascoux-combe et al., Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCVcoinfected patients, and factors associated with HAV and HBV vaccination, Vaccine. 3 nov, vol.29, issue.47, pp.8656-60, 2011.

M. Mohseni-zadeh, D. Rey, M. Batard, B. Wirth, G. Partisani et al., Insuffisance de couverture vaccinale d???une cohorte fran??aise de patients s??ropositifs VIH, M??decine et Maladies Infectieuses, vol.40, issue.12, pp.683-90, 2010.
DOI : 10.1016/j.medmal.2010.06.005

O. Launay, S. Grabar, E. Gordien, C. Desaint, D. Jegou et al., Immunological Efficacy of a Three-Dose Schedule of Hepatitis A Vaccine in HIV-Infected Adults: HEPAVAC Study, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.49, issue.3, pp.272-277, 1999.
DOI : 10.1097/QAI.0b013e318183a9c0

Y. Tseng, S. Chang, W. Liu, H. Sun, C. Wu et al., Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men, Hepatology, vol.57, issue.5, pp.1734-1775, 2013.
DOI : 10.1097/QAI.0b013e31821fdec3

E. Grilli, A. Baiocchini, F. Nonno, N. Petrosillo, and V. Galati, Fulminant VZV infection in an adult AIDS patient treated with steroids: A case report, Journal of Clinical Virology, vol.60, issue.1, pp.63-69, 2014.
DOI : 10.1016/j.jcv.2014.02.008

B. Khoshnood, M. Debruyne, F. Lançon, C. Emery, F. Fagnani et al., Seroprevalence of Varicella in the French Population, The Pediatric Infectious Disease Journal, vol.25, issue.1, pp.41-45, 2006.
DOI : 10.1097/01.inf.0000195636.43584.bb

J. Palefsky, A. Giuliano, S. Goldstone, E. Moreira, C. Aranda et al., HPV Vaccine against Anal HPV Infection and Anal Intraepithelial Neoplasia, 1576?85. 75. HCSP. Recommandations vaccinales contre les infections à papillomavirus humains chez les hommes [Internet] Disponible sur, 2011.
DOI : 10.1056/NEJMoa1010971

E. Chiron, M. Jauffret-routside, L. Strat, Y. Chemlal, K. Valantin et al., Prévalence de l'infection par le VIH et le virus de l'hépatite C chez les personnes détenues en France. Résultats de l'enquête Prévacar 2010, 35?36):445?50. 77. HIV causal collaboration. When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries: An Observational Study, p.509, 2011.

C. Larsen, G. Pialoux, and D. Salmon, Prévalence des co-infections par les virus des hépatites B et C dans la population VIH, France, juin, BEH BEH. Juin, vol.23, issue.23, pp.109-112109, 2004.

J. Guthmann, L. Fonteneau, D. Anthona, and D. Levy-bruhl, La couverture vaccinale diphtérie, tétanos, poliomyélite chez l'adulte en France: résultats de l'enquête Santé et Protection sociale, Bull Epidemiol Hebd, vol.441, issue.5, pp.51-53, 2002.

/. Pneumocoque and I. Données, Maladies infectieuses / Dossiers thématiques / Accueil [Internet] Disponible sur: http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies- infectieuses/Maladies-a-prevention-vaccinale/Couverture- vaccinale, 2017.

J. Guthmann, Couverture vaccinale contre le grippe saisonnière dans les groupes cibles et mesure de l'efficacité vaccinale. Couverture vaccinale par les vaccins diphtérietétanos-poliomyélite (dTP) et antipneumococcique chez les personnes âgées de 65 ans et plus, 2011.

A. Duburcq, L. Courouve, and N. Vanhaverbeke, Evaluation auprès des parents du carnet de santé n°CERFA 12593*01 (modèle en vigueur depuis le 1er janvier 2006) Evaluation réalisée pour la DGS, Disponible sur, p.2012, 2016.

D. Antona, L. Fonteneau, D. Lévy-bruhl, N. Guignon, D. Peretti et al., Couverture vaccinale des enfants et des adolescents en France: résultats des enquêtes menées en milieu scolaire, Bull Epidemiol Hebd, vol.6, pp.45-54, 2001.

J. Guthmann, L. Fonteneau, C. Ciotti, E. Bouvet, G. Pelissier et al., Couverture vaccinale des soignants travaillant dans les établissements de soins de France. Résultats de l'enquête nationale Vaxisoin, Bull Epidemiol Hebd. 09, issue.35?36, pp.371-377, 2009.

/. Grippe and I. Données, Disponible sur: http://invs.santepubliquefrance.fr/Dossiers- thematiques/Maladies-infectieuses/Maladies-a-prevention-vaccinale/Couverture- vaccinale, Maladies infectieuses / Dossiers thématiques / Accueil [Internet], 2016.

S. Vaux, D. Van-cauteren, J. Guthmann, L. Strat, Y. Vaillant et al., Influenza vaccination coverage against seasonal and pandemic influenza and their determinants in France: a cross-sectional survey, BMC Public Health, vol.10, issue.42, 2011.
DOI : 10.1186/1471-2458-10-159

B. Hépatite and I. Données, Disponible sur: http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies- infectieuses/Maladies-a-prevention-vaccinale, Maladies infectieuses / Dossiers thématiques / Accueil [Internet], 2017.

L. Fonteneau, J. Guthmann, and D. Levy-bruhl, Estimation des couvertures vaccinales à 24 mois à partir des certificats de santé du 24eme mois, 2004.

F. Collange, L. Fressard, P. Verger, F. Josancy, R. Sebbah et al., Vaccinations: attitudes et pratiques des médecins généralistes, Etudes Result. mars, issue.910, pp.1-8, 2015.

F. Collange, L. Fressard, C. Pucini, O. Launay, A. Gautier et al., Opinion des médecins généralistes de la région Provence-Alpes-Côte d'Azur sur le régime obligatoire ou recommandé des vaccins en population générale, BEH. juillet, issue.24?25, pp.406-419, 2015.

. Vaccins-combinés-contenant-la-valence-coqueluche, Tensions d'approvisionnement - ANSM : Agence nationale de sécurité du médicament et des produits de santé [Internet] Disponible sur: http://ansm.sante.fr/S- informer/Informations-de-securite-Ruptures-de-stock-des-medicaments/Vaccins- combines-contenant-la-Valence-Coqueluche-Tensions-d-approvisionnement, 2017.

H. Larson, A. De-figueiredo, Z. Xiahong, W. Schulz, P. Verger et al., The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey, EBioMedicine, vol.12, pp.295-301, 2016.
DOI : 10.1016/j.ebiom.2016.08.042

F. Collange, L. Fressard, C. Pulcini, R. Sebbah, P. Peretti-watel et al., General practitioners??? attitudes and behaviors toward HPV vaccination: A French national survey, Vaccine, vol.34, issue.6, pp.762-770, 2016.
DOI : 10.1016/j.vaccine.2015.12.054

P. Verger, L. Fressard, F. Collange, A. Gautier, C. Jestin et al., Vaccine Hesitancy Among General Practitioners and Its Determinants During Controversies: A National Cross-sectional Survey in France, EBioMedicine, vol.2, issue.8, pp.891-898, 2015.
DOI : 10.1016/j.ebiom.2015.06.018

J. Raude, L. Fressard, A. Gautier, C. Pulcini, P. Peretti-watel et al., Opening the ???Vaccine Hesitancy??? black box: how trust in institutions affects French GPs??? vaccination practices, Expert Review of Vaccines, vol.41, issue.347, pp.937-985, 2016.
DOI : 10.1057/9780230627611

URL : https://hal.archives-ouvertes.fr/hal-01452881

I. and S. France, Etude qualitative sur la vaccination auprès du grand public et des professionnels de santé, Juin, 2016.

A. Gauthier and I. , Baromètre santé INPES: des données complémentaires à celles des couvertures vaccinales. 9èmes journées de la prévention, 2014.